(S)-Diethyl 2-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-ylamino)-2-oxoethylphosphonate
98%
- Product Code: 38142
CAS:
618061-76-0
| Molecular Weight: | 552.92 g./mol | Molecular Formula: | C₂₄H₂₇ClFN₄O₆P |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD19440885 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8°C, protected from light, stored in an inert gas |
Product Description:
This compound is primarily utilized in the development of targeted cancer therapies, particularly as an inhibitor of specific tyrosine kinases involved in tumor growth and proliferation. Its structure allows it to bind selectively to kinase domains, disrupting signaling pathways that promote cancer cell survival. Researchers explore its potential in treating cancers such as non-small cell lung cancer and breast cancer, where aberrant kinase activity is often observed. Additionally, it is studied for its efficacy in overcoming resistance to existing kinase inhibitors, offering a promising avenue for improved therapeutic outcomes. Its phosphonate group enhances cellular uptake and stability, making it a valuable candidate for further drug development and clinical trials.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | White to light-yellow powder or crystals |
| PURITY | 97.5-100 |
| Infrared spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.100 | 10-20 days | ฿13,000.00 |
+
-
|
| 0.250 | 10-20 days | ฿20,600.00 |
+
-
|
| 1.000 | 10-20 days | ฿46,350.00 |
+
-
|
(S)-Diethyl 2-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-ylamino)-2-oxoethylphosphonate
This compound is primarily utilized in the development of targeted cancer therapies, particularly as an inhibitor of specific tyrosine kinases involved in tumor growth and proliferation. Its structure allows it to bind selectively to kinase domains, disrupting signaling pathways that promote cancer cell survival. Researchers explore its potential in treating cancers such as non-small cell lung cancer and breast cancer, where aberrant kinase activity is often observed. Additionally, it is studied for its efficacy in overcoming resistance to existing kinase inhibitors, offering a promising avenue for improved therapeutic outcomes. Its phosphonate group enhances cellular uptake and stability, making it a valuable candidate for further drug development and clinical trials.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :